KeDi

Quick links to important sections

KeDi

Treatment option: Cough

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of KeDi

Quick Facts

Property Description
Active ingredient Dextromethorphan Hydrobromide (DXM)
Form Syrup, Oral Solution, Tablets, Capsules
Pharmacological class Antitussive Agent (Cough Suppressant)
Common use Suppression of the cough reflex
Origin Synthetic, Non-Opioid Derivative

What is KeDi? Defining its Pharmacological Identity

KeDi is a proprietary trade name for a medicine classified as an antitussive agent, which means its primary function is to provide symptomatic relief by acting as a cough suppressant. This places the drug within the specific pharmacological class of agents designed to control the cough reflex, distinguishing it from other respiratory medicines. The core identity of KeDi is defined by its single active component, Dextromethorphan Hydrobromide (DXM), a compound that is recognized for its central antitussive properties. This designation confirms its general purpose is the selective interruption of persistent, non-productive coughing, such as the dry cough often experienced during a viral respiratory illness.

Composition and Source: Is KeDi a Non-Opioid Derivative?

The active ingredient, Dextromethorphan Hydrobromide, is a synthetic compound derived from a chemical family related to opioids, but it is fundamentally classified as a non-opioid derivative. This is an important distinction confirming that the substance operates outside of the typical opioid receptor pathways. The structure of DXM, which is a methylated, dextrorotatory analogue, confirms its synthetic origin. This characteristic ensures it functions through unique mechanisms separate from those of classic narcotic cough medicines.

Form and General Purpose

KeDi is intended for the oral route of administration, and it is typically available in common dosage forms including syrup or oral solution, as well as solid forms like tablets and capsules. The primary utility of these forms is to provide a readily absorbable source of Dextromethorphan Hydrobromide for the systemic suppression of the cough reflex. This therapeutic goal is achieved through its central action on the medullary cough center, which is the fundamental mechanism allowing the medication to calm the urge to cough.

What side effects are possible with KeDi?

Possible Side Effects and Safety Information

The safety profile of Dextromethorphan Hydrobromide (KeDi) is categorized in official regulatory documents based on the body systems affected and the frequency of occurrence. At therapeutic doses, the adverse reactions are typically classified as Uncommon, affecting a small fraction of patients.

Adverse Reaction Classifications

System-Organ Class Examples of Documented Effects Frequency Classification
Nervous System Disorders Drowsiness (somnolence), Dizziness Uncommon
Gastrointestinal Disorders Nausea, Vomiting, Abdominal discomfort Uncommon
Immune System/Skin Hypersensitivity reactions (e.g., rash, urticaria) Not Known

Serious Safety Considerations

Official labeling emphasizes the risk of Serotonin Syndrome, a potentially life-threatening event that has been reported when this medicine is used alongside certain other drugs, such as Monoamine Oxidase Inhibitors (MAOIs) or Selective Serotonin Reuptake Inhibitors (SSRIs). This serious risk is the basis for a strict Contraindication against concurrent use with MAOIs.

Furthermore, regulatory documents note that massive overdose is associated with severe toxicity, including respiratory depression, seizures, and cardiotoxicity. Safety notes also state that prolonged use may be associated with the development of drug dependence.

Population-Specific Safety Notes

Safety constraints apply to specific populations and conditions. Use is generally cautioned or restricted in individuals with moderate to severe hepatic impairment due to the drug’s metabolism. The medicine is also typically contraindicated for patients who are at risk of, or who have, respiratory failure.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation defines the Dextromethorphan Hydrobromide (KeDi) overdose profile by specific clinical manifestations and mandated emergency actions.

Documented Overdose Manifestations

Category Officially Documented Signs
Central Nervous System (CNS) Agitation, confusion, dizziness, somnolence, nystagmus (involuntary eye movement), ataxia, and tremors.
Gastrointestinal Nausea and vomiting.

Severe and Life-Threatening Outcomes

Regulatory authorities note the potential for severe toxicity, including profound CNS depression, seizures, and respiratory depression. A documented risk is the development of Serotonin Syndrome, characterized by symptoms such as agitation, hyperthermia, and rapid heart rate. Overdose in young children is associated with increased severity, particularly concerning respiratory function.

Required Emergency Actions

In the event of a suspected overdose, regulatory guidelines strictly mandate that the user contact a Poison Control Center or seek immediate medical help. Management in a clinical setting is defined as symptomatic and supportive treatment. Procedures described in official labeling may include the use of activated charcoal for gastrointestinal decontamination and the administration of Naloxone to counteract severe respiratory or CNS depression. Continuous hospital monitoring of vital signs and neurological status is often required for symptomatic individuals.

Therapeutic Uses of KeDi

What KeDi Treats: Main Uses and Benefits

KeDi is generally used to provide temporary symptomatic relief from cough, aligning with therapeutic domains where short-term symptomatic assistance is needed to manage distressing manifestations. The medication is applied across conditions presenting with acute episodes, including coughs caused by the common cold, the flu, or minor throat and bronchial irritation.

Relief for Disruptive Cough

The primary therapeutic value is applied in addressing a disruptive cough impulse. It is most relevant for managing the symptoms that interfere with daily functioning—specifically the dry, hacking, and non-productive cough pattern. By addressing this relentless urge, KeDi contributes to improved comfort during periods of heightened symptoms. This contributes to easing the episode and may assist with maintaining functional stability, particularly regarding rest and sleep.

“The primary goal of this symptomatic support is to ease the overall burden of a dry, irritating cough.”


Quick Fact: Relief for Dry Cough

The medication is relevant when supportive symptom management is appropriate for coughs driven by minor irritation rather than excessive mucus production. It is used to help manage symptoms that become more disruptive during flare-ups.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use KeDi? Official Eligibility

The official eligibility profile for KeDi (Dextromethorphan Hydrobromide) establishes precise population constraints based on government regulatory documentation.

Absolute Contraindications

Use is strictly forbidden for individuals with a documented hypersensitivity to the drug or any component. It is also contraindicated for patients currently taking or having taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days, as well as those with acute asthma or existing respiratory insufficiency.

Age-Related Eligibility

The medicine is generally approved for adults and children 12 years and older. Regulatory guidance restricts or prohibits use in children under 12 years, with an absolute prohibition on administration to children under 4 years.

Conditional Restrictions

Use is restricted for chronic or persistent cough (such as cough associated with smoking or chronic bronchitis) and coughs accompanied by excessive secretions (phlegm), unless specific medical guidance is provided.

Physiological Constraints

Use is generally not recommended during pregnancy and lactation due to insufficient established safety data. Caution and medical consultation are also required for patients with documented hepatic (liver) impairment or severe renal (kidney) impairment.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products

KeDi (Dextromethorphan Hydrobromide) interacts with several medicinal products and substances through officially documented pharmacokinetic and pharmacodynamic pathways.

Classification Official Regulatory Documentation Statement
Contraindicated Combination Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited.
Timing-based Rule A mandatory 14-day washout period is required when switching between KeDi and any MAOI.

The primary pharmacokinetic concern centers on the CYP2D6 enzyme system. Potent CYP2D6 inhibitors (e.g., Quinidine, Fluoxetine, Paroxetine) are documented to reduce KeDi’s clearance, resulting in a substantial increase in systemic exposure (plasma concentration). This effect is formally noted to be more pronounced in CYP2D6 Poor Metabolizers, a population-specific consideration.

Pharmacodynamic interactions involve additive effects. Co-use with other serotonergic agents (e.g., SSRIs, Triptans) elevates the regulatory-defined risk of Serotonin Syndrome. Combining KeDi with any CNS depressant, including alcohol, is documented to increase additive CNS effects. Additionally, interaction cautions extend to Grapefruit Juice due to its potential to inhibit KeDi's metabolism.

This structure is based on the absolute prohibition with MAOIs and the central role of CYP2D6 inhibition, which collectively establish the regulatory restrictions for co-use across multiple drug categories.

Mechanism of Action

KeDi functions as a highly selective allosteric antagonist of the P2Y12 receptor, a G-protein-coupled receptor (GPCR) predominantly expressed on the surface of circulating platelets. Its mechanism involves binding to a distinct site on the receptor, inducing a conformational change that prevents the binding and signaling action of the endogenous agonist, adenosine diphosphate (ADP).

This allosteric modulation interrupts the G i-protein-mediated intracellular signaling cascade. Specifically, P2Y12 inactivation prevents the resulting inhibition of adenylyl cyclase (AC) activity, maintaining elevated levels of cyclic AMP (cAMP) within the platelet cytosol. Simultaneously, the compound modulates the downstream G q-mediated activation pathways.

By disrupting these signaling pathways, KeDi inhibits the conformational change and subsequent activation of the glycoprotein IIb/ IIIa complex, which is integral to platelet aggregation. This cellular process results in the modulation of primary hemostasis at a system level, limiting the formation of fibrinogen cross-links between platelets.

Dosage and Administration Information

How to use KeDi: Official Administration Guidelines

The administration of KeDi (Dextromethorphan Hydrobromide) is dictated by official instructions detailing the approved route, dosage schedule, and usage duration, confining its use to established protocols.


Administration Scope

Instruction Detail
Route of Administration Strictly oral route for all approved dosage forms, including liquids and tablets.
Standard Dosing Schedule 10 mg to 20 mg per dose every four hours OR 30 mg per dose every six to eight hours for immediate-release adult dosing. The total authorized dose is strictly limited not to exceed 120 mg in a 24-hour period.
Timing/Preparation Liquid forms require the bottle to be shaken well before use and the dose measured accurately using a calibrated device only. Extended-release solid forms must be swallowed whole and are prohibited from being chewed or crushed.
Age-Group Rules The medication is not authorized for administration to children under four years of age. Specific, lower, age-based dosing schedules apply to older children.

Procedural Structure and Constraints

The official use protocol establishes that the oral administration is regulated by specific time intervals, such as every four or twelve hours, depending on the formulation. This protocol is intended for short-term use only, typically not exceeding seven consecutive days. The instructions prohibit exceeding the 120 mg daily maximum and mandate careful handling of the dosage form to maintain the intended drug release profile, which is particularly relevant for extended-release products.

Recent Clinical Evidence

Research Evidence: Overview of Studies for KeDi


Evidence for Use in Acute Cough from Colds

Research exploring KeDi (Dextromethorphan Hydrobromide) for antitussive use relies mainly on short-term, placebo-controlled, double-blind Randomized Controlled Trials (RCTs). These are study designs intended to limit the influence of confounding factors by randomly assigning participants to receive either the medicine or an inactive placebo. Research has been applied in studies examining patient-reported experiences of cough symptoms, which are conditions characterized by fluctuating or episodic manifestations.

In these trials, researchers monitored several key outcomes related to physical discomfort. They used objective cough counters to measure changes in total cough frequency and also recorded patient-reported outcomes describing perceived discomfort, such as cough severity scores. Findings describe patterns observed in the studies where some trials reported a statistically measurable difference in outcomes compared to a placebo, though the practical significance of this change was further examined in scientific reviews. However, other similar trials reported that the findings were mixed, showing no statistically significant difference.

Research Comparisons and Placebo Findings

The design of the research has consistently compared KeDi against an inactive placebo to observe any differences in the measured outcomes. The high response rate from the placebo group is a factor that complicated the ability of trials to clearly identify the independent influence of the active agent. When differences were observed in some studies compared to placebo, the measured change was often described in scientific literature as having a small practical size. KeDi was also evaluated in some studies that included other non-opioid antitussive agents as comparators.


Evidence in Specific Age Groups

KeDi was evaluated in studies involving both adults and children (typically ages 6 and older) with acute cough associated with the common cold. The results apply only to the populations studied and data on infants or very young children remain limited, as these groups are typically excluded from these types of trials. Research largely focuses on generally healthy populations experiencing an acute respiratory episode.


Key Limitations and Areas of Scientific Uncertainty

One key issue is the inconsistency of findings across different randomized trials, meaning certainty remains low when synthesizing all the research. Furthermore, long-term effects are not fully established, as the follow-up durations were limited, typically lasting only 4 to 7 days, and the research provides context but not individual predictions about personal outcomes.

Key Studies & References

  1. Systemic review of randomized controlled trials of over the counter cough medicines for acute cough in adults
  2. Objective and self-reported evidence of dextromethorphan antitussive efficacy in children, aged 6-11 years, with acute cough due to the common cold
  3. Cough (acute): antimicrobial prescribing - Summary of the evidence (NICE Guideline)
  4. Dextromethorphan: MedlinePlus Drug Information (Authoritative Patient Information)
  5. Dextromethorphan (Regulatory and Safety Monograph) - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about KeDi (FAQ)


Q: Do I need to change my diet while taking KeDi?

Regulatory documents do not require general diet modification while using KeDi. However, the official product information does specifically advise against drinking alcohol due to the increased risk of certain central nervous system side effects.


Q: How quickly does KeDi start to work?

Official documents, while not specifying a precise time, indicate that the active ingredient in KeDi is rapidly absorbed by the body. Consequently, the cough-suppressing effects may be expected to begin shortly after the medication is administered.


Q: Is KeDi a controlled substance?

According to the U.S. Drug Enforcement Administration (DEA), the active ingredient in KeDi is not classified as a controlled substance under the Controlled Substances Act. This means it is not subject to the same strict dispensing and tracking rules as narcotic pain relievers.


Q: Can I miss a dose of KeDi without major problems?

Regulatory information indicates that KeDi is often taken 'as needed' based on a frequency schedule, rather than for a chronic condition. For this type of medication, missing one dose does not typically result in major problems. Regulatory guidance suggests following the dosing schedule advised by a healthcare professional.


Q: What are the most commonly reported side effects of KeDi?

Official regulatory documents list common side effects that are usually temporary and classified as uncommon. These include effects such as dizziness, drowsiness, and mild gastrointestinal issues like nausea and stomach pain.


Q: Does KeDi interact with common pain relievers like ibuprofen?

Regulatory information on drug interactions focuses on specific chemical classes that interact with KeDi's metabolism or central nervous system activity. While the product label may not list a direct interaction with pain relievers like ibuprofen, it is important that any patient reviews their full medication and supplement list with a pharmacist or healthcare provider.


Q: What happens if I stop taking KeDi suddenly?

Because the medication is intended for short-term, temporary relief, the sudden cessation of therapeutic doses does not typically lead to withdrawal effects. Regulatory labels address dependence primarily as a risk associated with drug abuse at high doses or prolonged use.


Q: Is KeDi known to affect fertility?

Regulatory documents include a nonclinical toxicology section that addresses potential effects on fertility. This information is based on studies performed in animals, and the implications of this information for human use are best reviewed by a healthcare professional.


Q: Why is KeDi prescribed for [Secondary condition if applicable]?

KeDi is primarily approved by regulatory authorities for use as an antitussive, which is a cough-suppressing medicine. However, the active ingredient is also approved for treating other specific neurological conditions, such as Pseudobulbar Affect (PBA), when used in certain combination drug formulations.


Q: Can KeDi cause changes in mood or behavior?

Official documents list central nervous system effects, such as nervousness, restlessness, and confusion, as possible adverse reactions. These types of effects have the potential to influence mood or behavior. In rare cases, massive overdose is associated with more severe psychiatric effects.


Q: Are there any foods or drinks that interact with KeDi?

Yes, regulatory warnings explicitly advise that the use of this product with alcohol should be avoided due to the documented risk of increased side effects. Official documents also include a caution against consuming grapefruit juice because it can affect how the body processes the medication.


Q: What is the half-life of KeDi (how long does it stay in the body)?

The half-life of the drug—the time it takes for half of the drug to be eliminated from the body—varies widely among individuals. The time can range from a few hours to nearly 20 hours, depending on a person's unique metabolic processes.


Q: What types of tests are usually needed before starting KeDi?

For the general, short-term use of KeDi as a cough suppressant, no specific medical tests are typically required beforehand. However, if the medication is used in specific combination drug formulations, regulatory warnings advise caution and potential monitoring (such as an ECG) for patients with certain risk factors.


Q: Can KeDi be taken with vitamins or supplements?

Regulatory documents advise caution when taking KeDi with any product that affects serotonin levels. This includes certain supplements. This warning is due to the potential risk of Serotonin Syndrome, which is a serious condition that can result from too much serotonin activity.


Q: Is KeDi associated with any serious allergic reactions?

Yes, official regulatory documents report that severe allergic reactions (hypersensitivity reactions) are possible, although they are considered rare. These reactions can include symptoms like a rash, hives, or swelling of the face and throat.


Q: Does KeDi interact with birth control pills?

The official regulatory labels for the active ingredient do not typically list interactions with hormonal contraceptives like birth control pills. Patients are generally advised to verify the compatibility of any over-the-counter medicine with their specific prescription medications with a healthcare professional.


Q: What is the target population for KeDi, descriptively?

The product is indicated by regulatory authorities for the temporary relief of cough caused by minor throat and bronchial irritation. Generally, the product is approved for use in adults and older children, but official guidelines establish strict prohibitions on use in very young children.


Q: Are there any warnings about operating machinery or driving while on KeDi?

Yes, regulatory warnings advise caution regarding activities requiring full mental alertness. Because side effects can include dizziness and drowsiness, patients are explicitly warned about operating machinery or driving until they understand how the drug affects them.


Q: What kind of monitoring is recommended while on KeDi?

For general use, no extensive monitoring is typically required. However, regulatory warnings stress the importance of monitoring for signs of Serotonin Syndrome if the product is taken alongside other medications that affect serotonin levels.


Q: Can KeDi affect my ability to think or concentrate?

Yes. The official product information lists side effects like drowsiness and dizziness, which are central nervous system effects. These effects can temporarily impair mental alertness and physical coordination, which directly affects the ability to think or concentrate.


Q: Are there any black box warnings associated with KeDi?

The official regulatory files confirm that there is no Black Box Warning associated with the active ingredient in its use as a cough suppressant. A Black Box Warning is the strongest warning the U.S. Food and Drug Administration (FDA) places on prescription drug labeling.


Q: Is KeDi available over the counter in any country?

Regulatory agencies in many jurisdictions, including the US, approve the active ingredient in KeDi for use in over-the-counter (OTC) products. It is widely available without a prescription for its intended use as a cough suppressant.


Q: Is it necessary to take KeDi at the same time every day?

Regulatory dosage instructions for this type of medication specify dosing frequency, such as every four or eight hours, indicating it is taken as needed for symptoms. This means it is usually not necessary to take KeDi at a fixed time every single day, unlike medications for chronic conditions.


Q: Does KeDi cause dry mouth or dehydration?

Regulatory documents do not commonly list dry mouth or dehydration as typical side effects of the medication. The active ingredient in KeDi is not generally associated with causing dehydration in its intended antitussive use.

How should KeDi be stored and disposed of?

Official Storage and Disposal Requirements

All storage and disposal instructions for KeDi (Dextromethorphan Hydrobromide) are based on governmental regulatory mandates to ensure product stability and safety.

Requirement Specification
Storage Temperature Store at controlled room temperature (20 C to 25 C) in the original, tightly closed container.
Environmental Constraints Protect from freezing, excessive heat, and moisture to maintain stability.
Child Safety Must be stored out of the sight and reach of children to prevent accidental ingestion.
Disposal Discard unused or expired medicine via a drug take-back program. If unavailable, mix with an undesirable substance (e.g., dirt) and seal in a bag before placing in household trash. Do not flush down the toilet.

These conditions are required to maintain product integrity up to the expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of KeDi found in:

A-Z Index: